SomaLogic expands its management team with new positions for


NEW YORK and BOULDER, Colorado, Aug.31, 2021 (GLOBE NEWSWIRE) – CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI data-driven proteomics technology, announced the nominations today recent years from Todd Johnson as Executive Vice President of Business Development and Strategy and Ruben Gutierrez, JD as General Counsel. In these roles, they will support SomaLogic’s efforts to expand its business growth and leverage the power of proteomics.

“We are honored to have these highly accomplished industry leaders join us at an exciting time in SomaLogic’s business expansion,” said SomaLogic President and Chief Operating Officer Melody Harris. “Todd and Ruben have the expertise and experience we need to move forward in the next evolution of our business.”

Todd Johnson will oversee SomaLogic’s business partnership portfolio. Prior to joining SomaLogic, he served as Senior Vice President for Care Transformation at AVIA, the leading national digital transformation partner for healthcare organizations. He was also CEO of HealthLoop, where he led the development of a digital platform that bridged communication between providers and patients, which was then deployed in more than 70 healthcare systems and hospitals. When HealthLoop was acquired by GetWellNetwork, Mr Johnson became the chief strategy officer for the company, where he realigned the company’s product portfolio to a more comprehensive outpatient and home model.

Prior to HealthLoop, Todd was the founding CEO of Baltimore-based Salar, Inc., an acute care documentation solution. Working with the country’s leading medical centers and physicians, he made Salar a successful acquisition in 2011 by Transcend Services, Inc. Transcend was, at the time, the second largest medical documentation company in the country. Todd holds a Bachelor of Computer Science degree from Cornell University.

As General Counsel, Ruben Gutierrez will advise the SomaLogic management team and ensure legal compliance across the organization. Prior to joining SomaLogic, he was Vice President of Legal and Corporate Affairs at Natera, Inc., a genetic testing company based in San Carlos, California. Previously, Mr. Gutierrez served as Legal Counsel to Human Longevity, Inc., a San Diego-based genomics research and health intelligence company, and was Legal Counsel in the Biosciences Division at Thermo Fisher Scientific, Inc.

Prior to his acquisition by Thermo Fisher Scientific, Ruben held positions of increasing responsibility within the legal group of Life Technologies Corporation. Mr. Gutierrez received an LL.M. in Taxation from New York University Law School, a JD from Gould Law School at the University of Southern California, and a BA from the University of California in Los Angeles.

About SomaLogic

SomaLogic seeks to provide accurate, meaningful and actionable health management information that enables individuals around the world to continuously optimize their personal health and well-being throughout their lives. This vital information, which is to be provided by a global network of partners and users, is derived from SomaLogic’s personalized measurement of significant changes in an individual’s proteins over time. For more information, visit and follow @somalogic on Twitter.

SomaSignal ™ assays are developed and their performance characteristics determined by SomaLogic, Inc. SomaLogic is a Laboratory Certified by the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP).

The SomaScan platform is for research use only (RUO) and has not been authorized or approved by the United States Food and Drug Administration for diagnostic or patient management purposes. SomaLogic’s proprietary SomaScan platform has been designed to be a universal platform that can be applied to research and discovery, translational research and biopharmaceutical development, as well as clinical applications. The SomaScan® The test measures 7,000 protein target measurements in a single sample as of April 30, 2021. The Company has analyzed more than 450,000 samples to date.

Forward-looking statements Disclaimer

This press release contains certain forward-looking statements within the meaning of federal securities laws regarding the proposed business combination between SomaLogic and CM Life Sciences II and others, including statements regarding the anticipated benefits of the business combination, the timing planned business combination, expansion plans, expected future results and market opportunities of SomaLogic. These forward-looking statements are generally identified by the words “believe”, “plan”, “expect”, “anticipate”, “estimate”, “intend”, “the strategy”, “the future”, “The opportunity”, “the plan,” “may”, “should”, “will”, “would”, “will”, “will continue”, “will probably result” and similar expressions. Forward-looking statements are predictions, projections and other statements regarding future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors. There are many factors that could cause actual future events to differ materially from forward-looking statements contained in this press release, including factors beyond the control of SomaLogic or CM Life Sciences II. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the CM Life Sciences II registration statement on Form S-4 (File No. 333-256127) (the “Registration Statement” ) and the declaration of definitive power of attorney / prospectus included therein. These documents identify and discuss important risks and uncertainties that could cause actual events and results to differ materially from those contained in forward-looking statements. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and SomaLogic and CM Life Sciences II assume no obligation and do not intend to update or revise these forward-looking statements, either at the following new information, future events or otherwise. Neither SomaLogic nor CM Life Sciences II gives assurance that SomaLogic or CM Life Sciences II or the combined company will achieve their expectations.


Leave A Reply